Biomea Fusion, Inc. (NASDAQ:BMEA) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Posted by Stanley Muller on Oct 3rd, 2026

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $9.00.

A number of research firms have recently issued reports on BMEA. Citigroup reiterated a “market outperform” rating on shares of Biomea Fusion in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Biomea Fusion in a research note on Monday, August 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a report on Monday. Finally, Wall Street Zen downgraded shares of Biomea Fusion from a “hold” rating to a “sell” rating in a report on Sunday, September 27th.

Read Our Latest Stock Report on BMEA

Institutional Investors Weigh In On Biomea Fusion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC bought a new stake in Biomea Fusion during the second quarter valued at $64,000. BlackRock Inc. acquired a new stake in shares of Biomea Fusion in the second quarter valued at approximately $1,052,000. GSA Capital Partners LLP acquired a new stake in Biomea Fusion in the 2nd quarter valued at approximately $318,000. Rathbones Group PLC bought a new stake in shares of Biomea Fusion during the first quarter valued at about $57,000. Finally, Renaissance Technologies LLC raised its position in shares of Biomea Fusion by 174.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock worth $2,009,000 after buying an additional 834,179 shares in the last quarter. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Trading Down 2.3%

BMEA stock opened at $1.27 on Monday. The company’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.46. Biomea Fusion has a twelve month low of $0.87 and a twelve month high of $2.99. The stock has a market cap of $92.05 million, a P/E ratio of -4.38 and a beta of -0.28.

Biomea Fusion (NASDAQ:BMEA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. On average, equities research analysts predict that Biomea Fusion will post -0.73 earnings per share for the current year.

About Biomea Fusion

(Get Free Report)

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for patients with cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to selectively target disease-associated proteins.

Biomea’s lead investigational product is icovamenib, also known as BMF-219, an oral covalent inhibitor of menin. The company has evaluated icovamenib in clinical studies for genetically defined blood cancers, including acute leukemias and multiple myeloma, as well as for type 2 diabetes and other metabolic conditions.